title: Risk of second primary malignancy in patients with AL amyloidosis treated with lenalidomide.
authors: Vaishali
authors: V
authors: Sanchorawala
authors: Anthony C
authors: AC
authors: Shelton
authors: Jerome B
authors: JB
authors: Zeldis
authors: David C
authors: DC
authors: Seldin
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000686:Amyloidosis / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000077269:Lenalidomide; D008297:Male; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000139:chemically induced / Q000401:mortality / Q000473:pathology; D012189:Retrospective Studies; D012307:Risk Factors; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D020533:Angiogenesis Inhibitors; D013792:Thalidomide; D000077269:Lenalidomide